Recent developments in immunotherapy of acute myeloid leukemia

Hyperthermia enhances bortezomib-induced apoptosis in human white blood cancer cells

Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions

Induction of Immune Response after Allogeneic Wilms‘ Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse

Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies

Long-term follow-up of patients with acute myelogenous leukemia receiving an autologous telomerase-based dendritic cell vaccine.

Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study

Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies

Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: Results of phase I study.